C2orf43 Inhibitors
Trichostatin A and 5-Azacytidine target the epigenetic machinery, which can indirectly influence the expression levels and functional state of C2orf43. The role of C2orf43 could be related to chromatin dynamics, and thus, HDACs and DNA methyltransferase inhibitors may alter its activity by changing the transcriptional landscape. Proteostasis is another potential avenue for indirect inhibition, with compounds like MG-132 and Cycloheximide acting to stabilize or deplete cellular levels of C2orf43. If C2orf43 is a short-lived protein, proteasome and protein synthesis inhibitors can respectively modulate its turnover or production rate.
Inhibitors like Rapamycin and LY294002, which target the mTOR and PI3K/AKT pathways, may affect C2orf43 indirectly by altering the signaling cascades that control cell growth, survival, and autophagy. These pathways are tightly regulated, and their modulation can lead to changes in various cellular functions, potentially including those associated with C2orf43. Kinase inhibitors such as Staurosporine and SP600125, as well as agents affecting nucleic acid synthesis and transport like Actinomycin D and Brefeldin A, can indirectly impact C2orf43 by disrupting the cellular networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An inhibitor of histone deacetylases (HDACs) that can modulate chromatin structure and gene expression, potentially affecting C2orf43 activity if it is regulated by chromatin remodeling. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that can alter DNA methylation patterns, potentially influencing the expression of C2orf43 if its regulation is epigenetically controlled. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can affect protein degradation pathways, potentially stabilizing C2orf43 if it is normally subject to proteasomal degradation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can modulate cell growth and autophagy pathways, potentially affecting C2orf43 if it is involved in these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that may impact the AKT signaling pathway, which can affect the stability or activity of C2orf43 if it is part of this pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent non-selective inhibitor of protein kinases that may alter signaling pathways regulating C2orf43 function. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
An inhibitor of eukaryotic protein synthesis that can halt the production of C2orf43, reducing its cellular levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
An inhibitor of DNA-dependent RNA synthesis that can suppress the transcription of C2orf43 if it is actively transcribed. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
An inhibitor of protein transport from the endoplasmic reticulum to the Golgi apparatus, potentially affecting the processing or trafficking of C2orf43. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule destabilizer that can disrupt cell division, potentially influencing C2orf43 if it plays a role in the cell cycle. | ||||||